Background : Gefitinib (Iressa) proved to be effective in patients with non-small cell lung cancer who had been placed on chemotherapy. Although Gefitinib was reported to cause limited serious toxic effects, a case of death by acute pulmonary disorder was reported in July 2002. Method : We administered Gefitinib to 55 patients during the period from August to December 2002 and three of them died of acute interstitial pneumonia. From these 55 patients, we selected 16 individuals who had a history of a certain lung disease or thoracic irradiation and discussed risk factors. Result : Of these 16 patients, three developed acute interstitial pneumonia approximately one month after the administration of Gefitinib. These patients were microbiologically and serologically diagnosed with acute interstitial pneumonia resulting from the treatment with Gefitinib. Conclusion : In the present study, we regarded fibrogenesis as a major risk factor for acute pulmonary disorder although we did not obtain this finding from all cases. ( (Table 1) . Of these 16 patients, three (cases 1, 2 and 3) developed acute interstitial pneumonia approximately one month after the administration of Gefitinib. These patients were microbiologically and serologically diagnosed with acute interstitial pneumonia resulting from the treatment with Gefitinib. The results obtained from case 2 were given in the figure so that the results of a CT scan of the patient's chest before the administration of Gefitinib (Fig. 1 ) could be compared with those of a CT scan at the time acute interstitial pneumonia developed (Fig. 2) . Although mild fibrogenesis was peripherally observed in the pretreatment film, bilateral diffuse ground-glass opacities were recognized at the time acute interstitial pneumonia developed. Similar findings were obtained at the time acute interstitial pneumonia developed in cases 1 and 3 ; both of them died approximately one month after large-dose steroid therapy and autopsies revealed diffuse alveolar damage. Of 16 patients, seven suffered from pulmonary emphysema and one from old pulmonary tuberculosis, although none of them showed any pulmonary disorder. A serious pulmonary disorder was recognized in two of four cases of pulmonary fibrosis and one of eight patients who had a history of thoracic irradiation. Mild fibrogenesis was observed in cases 2 and 3, while mild fibrogenesis resulting from radiation pneumonitis due to therapeutic irradiation six months before was detected in the right upper lobe in case 1. There were no significant differences in other factors such as the PS, age or the presence of complications in this patient group. In the present study, we regarded fibrogenesis as a major risk factor for acute pulmonary disorder although we did not obtain this finding from all cases. We speculate that other factors seem to be involved in the acute pulmonary disorder developing although we can not identify the causative factor because of the paucity of patients. Bearing in mind that Gefitinib possesses high toxicity, we would like to urgently evaluate the indication of treatment with Gefitinib and the risk factors. 
